Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01611207
Other study ID # 03-2012
Secondary ID DRKS ID 00003498
Status Terminated
Phase N/A
First received March 28, 2012
Last updated May 17, 2013
Start date June 2012
Est. completion date June 2014

Study information

Verified date May 2013
Source University of Witten/Herdecke
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Negative Pressure Wound Therapy (NPWT) or Standard Conventional Wound Therapy (SCWT) are effective in the treatment of Iatrogenic Subcutaneous Abdominal Wound healing-impairments (ISAW).


Description:

The aim of the study is the comparison between NPWT and Standard Conventional Wound Therapy (SCWT) under clinical, safety and economic aspects in the treatment of postoperative Iatrogenic Subcutaneous Abdominal Wounds (ISAW). The hypothesis is based on the assumption that the application of NPWT for the treatment of postoperative abdominal wound healing impairments (with intact fascia) results in a decrease of time until achievement of wound closure (with confirmation after 30 consecutive days) and for this reason more wound closures can be achieved in the maximum treatment period of 42 days compared to the control therapy.


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date June 2014
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Acute subcutaneous abdominal wound-healing impairment after surgical intervention

- Sizes of wound opening (maximum diameter = 3 cm)

- Wound surface = 9 qcm

Exclusion Criteria:

Lack of infrastructure for outpatient continuation of treatment and study-specific interventions

- Existence of an open abdominal fascia

- Acute serious organ failure

- Application of an other active vacuum device at the wound treated during the study conduct within 8 days before screening visit

- Ongoing / during 3 weeks after chemo therapy

- Ongoing / during 3 weeks after radiation therapy Contraindications in accordance with the safety precautions issued by the FDA or the companies

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
Negative Pressure Wound Therapy
KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith & Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
Other:
Standard Wound Therapy
Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)

Locations

Country Name City State
Germany St. Marien-Krankenhaus Ahaus-Vrede Ahaus
Germany Asklepios Stadtklinik Bad Tölz GmbH Bad Tölz
Germany Bundeswehrkrankenhaus Berlin Berlin
Germany Klinikum Bilefeld - Mitte Bielefeld
Germany Knappschaftskrankenhaus Bochum der Ruhr Bochum
Germany Klinikum Darmstadt, Chirurgische Klinik III Darmstadt
Germany Diakonissenkrankenhaus Dessau /Roßlau Dessau /Roßlau
Germany Krankenhaus Düren gem. GmbH Düren
Germany Klinik für Gefäß- und Endovascular-Chirurgie, Klinikum der Johann Wolfgang Goethe - Universität Frankfurt am Main
Germany Krankenhaus Martha-Maria Halle-Dölau Halle (Saale) Sachsen-Anhalt
Germany Krankenhaus St. Elisabeth und St. Barbara, Klinik für Allgmein- und Visceralchirurgie Halle (Saale)
Germany Universitätsklinikum Halle/Saale, Allgemein-, Viszeral- und Gefäßchirurgie Halle (Saale)
Germany Asklepios Westklinikum Hamburg Hamburg
Germany Sana Klinikum Hameln-Pyrmont Klinik für Allgemein- und Visceralchirurgie Hameln
Germany Gemeinschaftskrankenhaus Herdecke Herdecke
Germany Universitätsklinikum Jena, Klinik für Allgemein-, Viszeral- und Gefäßchirurgie Jena
Germany Universitätsklinikum Jena, Klinik für Frauenheilkunde und Geburtshilfe, Abt. Gynäkologie Jena
Germany Westpfalz-Klinikum GmbH, Klinikum für Allgemein-, Viszeral- und Transplantationschirurgie Kaiserslautern
Germany Städtisches Klinikum Karlsruhe gGmbH, Klinik für Allgemein- und Viszeralchirurgie Karlsruhe
Germany Kliniken der Stadt Köln Krankenhaus Merheim, Klinik für Visceral-, Gefäß- und Transplantationschirurgie Köln-Merheim
Germany Universitätsklinikum Schleswig-Holstein, Klinik für Chirurgie Lübeck
Germany Klinik und Poliklinik für Allgemein- und Abdominalchirurgie, Johannes Gutenberg- Universität Mainz
Germany Wundzentrum München München
Germany Klinikum der Universität München, Chirurgische Klinik und Poliklinik München-Großhadern
Germany Universitätsklinikum Münster, Klinik für Allgemein und Viszeralchirurgie Münster
Germany Städtisches Klinikum Neunkirchen Neunkirchen/Saar
Germany Ortenauklinikum Offenburg-Gengenbach Offenburg
Germany Klinikum Dorothea Christiane Erxleben Quedlinburg
Germany Carl-von-Basedow Klinikum, Saalekreis Querfurt
Germany Zentrum für Gefäßmedizin Klinikum Südstadt Rostock Rostock
Germany Asklepios Klinikum Uckermark GmbH, Klinik für Allgemein- und Visceralchirurgie Schwedt
Germany Agaplesion Bethesda-Krankenhaus Stuttgart Stuttgart
Germany HSK Dr. Horst Schmidt Kliniken Wiesbaden
Germany Evangelisches Krankenhaus Paul Gerhardt Stift, Allgemein-, Viszeral- und Gefäßchirurgie Wittenberg

Sponsors (3)

Lead Sponsor Collaborator
University of Witten/Herdecke Kinetic Concepts, Inc., Smith & Nephew Wound Management Inc

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Wound closure Time-of-closure (in days) achieved and confirmed wound closures and rate-of-closure (in number). The wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material.
The closure must remain at least for a period of 30 days.
within 42 days of treatment No
Secondary Wound volume Reduction of wound volume (cubic centimeter) in the course of treatment. within the observation period of 180 days No
Secondary Wound infections Number of wound infections over the time. within the observation period of 180 days No
Secondary Recurrences Number of recurrences over the time. wthin observation period of 180 days No
Secondary Pain within a maximum treatment time of 42 days No
Secondary Quality of Life EQ-5D at inclusion, end of maximum treatment time or end of therapy, Follow-Up after 180 days. within observation period of 180 days No
Secondary Direct costs direct medical resource use and costs: hospitalization, outpatient contact with study centre and other providers, reimbursable drugs, medical sundries, adjuvants, reimbursable services direct non-medical resource use and costs: services, travel costs, expenditure of time for patients, expenditure of time for lay care within a maximum treatment time of 42 days or until end of therapy No
Secondary Indirect costs Disability, disability pension, premature death within a maximum treatment time of 42 days or until end of therapy No
Secondary Serious adverse events within the observation period of 180 days Yes
Secondary Adverse events Wound- and device-specific adverse events within a maximum treatment time of 42 days Yes